Tech vendors team up for closed loop trial
SAN DIEGO – A National Institutes of Health-funded International Diabetes Closed Loop Trial starting later this year will combine technologies from Tandem Diabetes Care, Dexcom and TypeZero Technologies. “The integration of technology provided by Tandem, Dexcom and TypeZero in this trial represents a new level of sophistication in artificial pancreas research and development,” said Boris Kovatchev, Ph.D., director of the Center for Diabetes Technology at the University of Virginia and principal investigator of the trial. A Tandem insulin pump and Dexcom G5 sensor will be included as part of a blood glucose control system that combines these devices with a smartphone running TypeZero’s inControl closed loop algorithm. The companies anticipate that the integrated design, together with data from the IDCL Trial, will be the basis for a future regulatory submission by Tandem. The trial will enroll 240 adults with Type 1 diabetes.
Accredited Home Care, QOLPOM team up for California telehealth
SANTA MONICA, Calif. – Accredited Home Care has signed with QOLPOM, Parallax Health’s telehealth subsidiary, to provide remote patient monitoring services to more than 15,000 patients in Los Angeles, Orange and San Diego counties. “Increasing our operational efficiencies and the quality of life of our patients is the aim of our partnership with QOLPOM and its leading technologies,” said Barry Berger, founder and CEO of Accredited Home Care, in a statement. QOLPOM will provide its technology to Accredited’s remote patient monitoring program, medication and compliance services, logistics, hardware and secure network platform management. “Our partnership with Accredited is a guiding light into the future and one that will showcase the very best nursing services working in combination with our groundbreaking technologies,” said Nathanial Bradley, QOLPOM president, in a statement.
Intuity Medical closes funding to launch automatic blood glucose monitoring system
SUNNYVALE, Calif. – Intuity Medical Inc. has closed a $40 million Series 3 round of funding to launch its POGO Automatic blood glucose monitoring system. “With this recent funding, we have the ability to bring POGO Automatic to the U.S. market for patients who have been looking for a convenient way to test their glucose,” said Emory Anderson, Intuity president and CEO, in a statement. The POGO system combines lancing, blood collection and analysis in one step. Combined with the company’s cloud-based Patterns Diabetes Management System, health care professionals and patients can share a platform for managing glucose information. POGO received clearance from the U.S. Food and Drug Administration in April.
Voice analyzing app may aid in heart disease diagnosis, study shows
ROCHESTER, Minn. – A Mayo Clinic study shows a possible relationship between voice characteristics and heart disease, and a new smartphone app from the voice analytics company Beyond Verbal might help. “Voice features analysis holds the potential to assist physicians in estimating the pre-test probability of (coronary artery disease) among patients presenting chest pain, especially in the setting of telemedicine,” the researchers said. Using Beyond Verbal’s smartphone app, the researchers identified 13 voice features associated with coronary artery disease. The strongest association between voice and coronary artery disease was observed when patients were asked to record their voice while describing a negative experience.
Pilot to look at how technology, monitoring can replace hospitalizations
BOSTON – PhysIQ and Vital Connect are working together in a pilot to evaluate how clinician visits to homes, combined with advanced continuous patient monitoring, can potentially replace hospitalizations for common medical admissions.
“The evolution of digital medicine makes us even more confident in the home hospital model for our patients,” said Dr. David Levine, the study’s principal investigator, in a statement. “We are in a very exciting era of medicine where clinical-grade biosensors and analytics are capable of delivering continuous physiological insight that was traditionally only available in the hospital environment.”
The pilot is taking place at Partners HealthCare Brigham and Women’s Hospital. It is the first of two planned initiatives to evaluate how technology and home-based care delivery can be leveraged to treat patients who would otherwise be admitted to the hospital.
As part of the randomized controlled trial, patients diagnosed at the BWH Emergency Department with exacerbation of heart failure, pneumonia, COPD, cellulitis or complicated urinary tract infection are provided with a home monitoring solution that includes the Vital Connect VitalPatch biosensor and physIQ Personalized Physiology Analytics platform.
“It’s extremely gratifying to know that leading institutions like Partners HealthCare and Brigham and Women’s Hospital are embracing the transformational potential of digital medicine,” said Gary Conkright, CEO of physIQ, in a press release.
The first phase of the pilot began in mid-September and involves up to 60 patients. Half of the patients are receiving traditional in-hospital treatment and half are receiving treatment at home. The pilot will scale up to 500 patients early next year.
“We see this initiative as proof of a new era of medicine,” said Dr. Nersi Nazari, CEO of Vital Connect, in a statement. “One where transformational models of care delivery are enabled by continuous ambulatory monitoring technology.”
PillDrill nabs Innovation Award, $3M funding
LAS VEGAS – PillDrill Inc. has closed $3 million in funding, and plans to use the new funds to grow its distribution channels.
The company has also been named a CES 2017 Innovation Awards Honoree in the Tech For a Better World category, and was recognized at the Consumer Technology Association’s “CES Unveiled New York” event earlier this month.
“We’re thrilled at the response to the product since our launch in April,” said Peter Havas, PillDrill’s founder and CEO, in a press release. “Medication adherence is a huge challenge across the board, and we’re committed to bringing PillDrill to the mass market to help solve it.”
PillDrill is an intuitive scanning system that simplifies the task of medication management with the PillDrill Hub, a device that sits next to the user’s pills and issues audio-visual alerts when doses are due. To indicate that a dose has been taken, the user waves the medication container in front of the Hub. Each scan triggers a real-time update to family members or concerned parties.
“Medication adherence is consistently one of the biggest challenges in health care, and throughout the years I’ve seen dozens of medical technology companies try and fail to addres sit,” said Annette Campbell-White, who recently joined PillDrill’s Board of Directors, in a statement. “I think PillDrill is the first medication management product people will actually want to use.”
miDIAGNOSTICS to use emocha platform for mobile health solution
BALTIMORE – miDIAGNOSTICS will collaborate with emocha Mobile Health to develop a mobile diagnostics lab and analytic platform.
“Adding emocha Mobile Health as a collaborator, we have chosen a top expert in the field of mobile health, connectivity and data management,” said Peter Peumans, vice president and program director of life science technology at imec, in a statement.
imec is the nanoelectrics research and development center collaborating with miDIAGNOSTICS and Johns Hopkins to develop diagnostic tests integrated in silicon chips that will act as miniaturized labs, able to detect cells, proteins, nucleic acids or small molecules from a tiny volume of body fluid. The emocha platform will connect the tests and their results to the laptops, tablets or smartphones of patients and caregivers through a mobile app, creating a mobile health solution for diagnostics at the point-of-need.
The system’s dashboard will offer a customizable view of test results, allowing test and data analysis.
“The cloud infrastructure is the central hub transforming future miDIAGNOSTICS products into impactful mobile health solutions that links patient results to providers and health systems electronic records,” said Hilja Ibert, CEO of miDIAGNOSTICS.
“Our mission is to help transform public health through mobile technology,” said Sebastian Seiguer, co-founder and CEO of emocha, in a statement.
Seiguer said the company hopes to be able to add this point-of-need testing to its mobile health interventions for a variety of use cases, including Hepatitis C medication adherence.
“Care has shifted rapidly to the outpatient setting, and our integrated solutions will enable providers to strongly support patients wherever they may be,” Seiguer said.
Studies show glycemic management system reduces readmissions
WALTHAM, Mass. – Glytec’s eGlycemic Management System helps reduce hospital readmissions, two new studies have found.
“The data indicates a direct correlation between risk-adjusted readmission rates and tight glycemic control for our cardiovascular patients,” said April Mumpower, BSH of Mountain States Health Alliance, one of the study’s leads, in a press release.
The two studies achieved reduced readmissions for patient populations at the center of new at-risk and value based reimbursement models, including the CMS Hospital Readmission Reduction Program (HRRP) and impending bundled payment for coronary artery bypass graft surgery (CABG).
The studies compared outcomes of cardiovascular patients receiving care with eGMS to outcomes of cardiovascular patients receiving standard care. Those receiving care with eGMS returned to the hospital far less frequently, with reductions in risk-adjusted 30-day readmissions as high as 68%.
One of the key benefits of Glytec’s eGMS is the GlucoSurveillance module that alerts care teams to patients with blood glucose outside a designated range. The module interfaces directly with laboratory information systems to perform continuous enterprise-wide surveillance.
The basis for the two studies was formed in response to a system-wide glycemic initiative launched by Mountain States Health Alliance. The researchers recognized that patients admitted and discharged with elevated blood glucose have higher incidence of complications, longer lengths of stays and increased rates of readmission.
“These studies validate our hypothesis that using Glytec’s automated surveillance, insulin dosing and analytics to achieve these goals has a sizable impact on the outcomes we’re able to achieve,” said Tamera Parsons, CPHQ of Blue Mountain States Health Alliance, and the co-lead of the studies.